Shots:

• J&J acquires TARIS Biomedical while TARIS to continue research in Lexington- Massachusetts and will also become part of Janssen R&D's Oncology Therapeutic Area. Additionally- the companies will focus on optimization of drug candidates for advancing and delivering future clinical programs utilizing TARIS technology
• The focus of an acquisition is to utilize TARIS’ drug delivery technology for advancing TAR-200 candidate further strengthening targeted oncologic therapy approach
• TARIS’ TAR-200 is an investigational candidate designed to release chemotherapeutic agent gemcitabine continuously in bladder for multiple weeks and has also received FDA’s Fast Track Designation in patients with organ-confined or locally advanced MIBC who are unfit for curative-intent therapy

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox